A new study presented at the European College of Neuropsychopharmacology (ECNP) Congress in Milan and published in The Lancet journal eClinicalMedicine revealed that psilocybin, the active compound in "magic mushrooms," may offer more effective outcomes for treating moderate to severe major depressive disorder compared to the commonly prescribed antidepressant escitalopram, a selective serotonin reuptake inhibitor (SSRI).